Browse the corpus

Clomipramine is a tricyclic antidepressant (TCA) that primarily exerts therapeutic effects through potent serotonin reuptake inhibition. This medication is FDA-approved to treat obsessive-compulsive disorder (OCD) in patients aged 10 and older. Clomipramine's off-label uses include depression, anxiety, insomnia, and chronic pain. This educational activity reviews the indications, mechanism of action, administration methods, contraindications, pharmacokinetics, monitoring, and toxicity associated with clomipramine administration. Understanding the pharmacology of clomipramine allows healthcare professionals to tailor treatment plans according to individual patient needs and provides a scientific basis for the practical management of OCD and related conditions. This activity emphasizes the role of the interprofessional healthcare team in managing clomipramine therapy for obsessive-compulsive disorder. The goal is to equip healthcare professionals with essential knowledge and tools for effective patient care during clomipramine administration, thereby advancing patient outcomes and care standards. This knowledge facilitates informed decision-making in prescribing clomipramine and optimizing dosage regimens while minimizing adverse effects. Objectives: Identify the indications for initiating clomipramine therapy. Assess the mechanism of action of clomipramine. Evaluate the contraindications for clomipramine therapy. Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from clomipramine therapy. Access free multiple choice questions on this topic.

Signs and Symptoms of Overdose Clomipramine toxicity is often associated with doses over 300 mg per day.[2] Toxicity with clomipramine can occur in overdose or if a patient is taking MAOI, S-RI, or drugs that inhibit CYP450 2D6. The most common symptoms seen in patients experiencing clomipramine toxicity include arrhythmias, seizures, and hypotension. Severe overdoses may also result in coma and death. Management of Overdose The antidote for TCAs is IV sodium bicarbonate (NaHCO3), along with supportive care of vital signs. When combined with an S-RI, MAOI, or other serotonergic medications, clomipramine may result in serotonin syndrome, which classically presents as a patient with the triad of altered mental status, myoclonus, and autonomic hyperactivity. The treatment for serotonin syndrome is cyproheptadine, along with appropriate supportive care.[35][36] Immediate management includes securing IV access, administering high-flow oxygen, attaching monitoring equipment, and performing endotracheal intubation. As clomipramine is a lipophilic TCA, lipid emulsion therapy can be used for patients who are hemodynamically unstable.[37] Lipid emulsion acts as a lipid sink, sequestering lipophilic clomipramine and reducing its harmful effects.[38]

Healthcare providers should monitor patients on clomipramine for metabolic effects and cardiac abnormalities by obtaining weight, BMI, fasting glucose, fasting lipid panel, BMP, magnesium, and electrocardiogram at baseline and routinely during treatment.[2] Providers, including all clinicians, specialists, pharmacists, and nurses with specialty training in psychiatric health, should also monitor for the risk of mania induction or suicidality as part of an interprofessional team approach to care. If patients on clomipramine experience adverse effects, the medication regimen should be titrated down or discontinued, or the patient should be referred to a psychiatrist or mental health nurse. A pharmacy consult is necessary to identify potential interactions, verify dosing, and make recommendations to the team as needed. In an overdose, emergency medicine physicians should rapidly stabilize the patient while coordinating with neurologists and psychiatrists. A poison control center/medical toxicologist should be consulted for complicated overdose. A randomized clinical trial showed that pharmacogenetics-informed treatment of TCAs resulted in faster attainment of therapeutic plasma concentrations and potentially fewer and less severe adverse effects.[39] The treatment outcomes associated with clomipramine for patients with OCD are superior to S-RIs. However, adverse effects limit medication tolerability; this is why an interprofessional team collaborating across disciplines can optimize the therapeutic benefits of clomipramine while minimizing adverse effects.[2]